# Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

> **NCT00005962** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** gemtuzumab ozogamicin
- **DRUG:** liposomal daunorubicin citrate
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00005962
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10-04
- **Primary completion:** 2005-10
- **Final completion:** 2007-06
- **Target enrollment:** — (—)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005962, "Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00005962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*